Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients

Blood (2015) 126 (23): 189.

https://doi.org/10.1182/blood.V126.23.189.189

Published: 2015

Journal Articles

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Alan K Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jamie Cavenagh, Jonathan Kell, MD MB, Gail Jones, Asim Khwaja, FRCPath, Mary Frances McMullin, MDFRCPath,FRCP, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 2308.

https://doi.org/10.1182/blood.V124.21.2308.2308

Published: 2014

Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 7.

https://doi.org/10.1182/blood.V124.21.7.7

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Michael Dennis, MD, Nigel H. Russell, MD, Nicki Panoskaltsis, MD, Claire Jane Hemmaway, MD, Donald Milligan, MD, Richard E Clark, MBBS MD, Robert K. Hills, MA MSc DPhil, Alan K Burnett, MD

Blood (2014) 124 (21): 3747.

https://doi.org/10.1182/blood.V124.21.3747.3747

Published: 2014

Journal Articles

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Ruben A. Mesa, MD, Jorge E. Cortes, MD, Francisco Cervantes, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Professor, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Florence Joulain, MSc, Sheikh Usman Iqbal, MD MPH MBA, Claire N Harrison, DM, FRCP, FRCPath

Blood (2013) 122 (21): 4061.

https://doi.org/10.1182/blood.V122.21.4061.4061

Published: 2013

Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc

Blood (2013) 122 (21): 1639.

https://doi.org/10.1182/blood.V122.21.1639.1639

Published: 2013

Journal Articles

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Annamaria Brioli, MD, Charlotte Pawlyn, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Samantha Marshall, Jindriska Lindsay, MD, Claire Chapman, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Michele Cavo, MD, Graham H Jackson, MD, Nigel Russel, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 2074.

https://doi.org/10.1182/blood.V122.21.2074.2074

Published: 2013

Journal Articles

Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants

Bhuvan Kishore, Daniel Wiseman, MBChB, MRCP, Emmanouil Nikolousis, Richard Lovell, Donald Milligan, MD, Kathy Holder, Lynn Bratby, Vidhya Murthy, Shankaranarayana Paneesha

Blood (2013) 122 (21): 5553.

https://doi.org/10.1182/blood.V122.21.5553.5553

Published: 2013

Journal Articles

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Charlotte Pawlyn, MD, Annamaria Brioli, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Jindriska Lindsay, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, Claire Chapman, MD, Roger G Owen, MD, Mark T Drayson, MD PhD, Nigel Russell, MD, Graham H Jackson, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 540.

https://doi.org/10.1182/blood.V122.21.540.540

Published: 2013

Journal Articles

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Alan K. Burnett, MD, David Bowen, MD, PhD, Nigel Russell, MD, Steven Knapper, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Asim Khwaja, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Dominic Culligan, Helen Clark, Robert K. Hills, MA, MSc, DPhil

Blood (2013) 122 (21): 622.

https://doi.org/10.1182/blood.V122.21.622.622

Published: 2013

Journal Articles

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Nigel Russell, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, David Bowen, MD, PhD, Mary Frances McMullin, MD

Blood (2013) 122 (21): 358.

https://doi.org/10.1182/blood.V122.21.358.358

Published: 2013

Journal Articles

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Claire N Harrison, DM, FRCP, FRCPath, Jorge E. Cortes, MD, Francisco Cervantes, MD, Ruben A. Mesa, MD, Donald Milligan, MD, FRCP, FRCPath, Tamás Masszi, MD, PhD, Elena Mishchenko, MD, Eric Jourdan, MD PhD, Alessandro M. Vannucchi, MD, Mark Drummond, MD PhD, Mindaugas Jurgutis, MD, Kazimierz Kuliczkowski, Emanuil Gheorghita, MD, Francesco Passamonti, MD, Frank Neumann, Guozhi Gao, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 393.

https://doi.org/10.1182/blood.V122.21.393.393

Published: 2013

Journal Articles

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Lone S. Friis, MD, PhD, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Michelle Lazenby, Amanda F Gilkes, MSc, David Bowen, MD, PhD, Nigel Russell, MD

Blood (2013) 122 (21): 493.

https://doi.org/10.1182/blood.V122.21.493.493

Published: 2013

Journal Articles

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Alan K. Burnett, Nigel H. Russell, Ann E. Hunter, Donald Milligan, Steven Knapper, Keith Wheatley, John Yin, Mary F. McMullin, Sahra Ali, David Bowen, Robert K. Hills

Blood (2013) 122 (8): 1384–1394.

https://doi.org/10.1182/blood-2013-04-496596

Published: 2013

Journal Articles

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Alan K. Burnett, MD, Nigel H Russell, MD, Jonathan Kell, MD, MB, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Paul Cahalin, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 892.

https://doi.org/10.1182/blood.V120.21.892.892

Published: 2012

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K Burnett, MD, Robert K Hills, MA, MSc, DPhil, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, John L Yin, MD, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Lars Kjeldsen, MD, PhD, David Bowen, Nigel H. Russell, MD

Blood (2011) 118 (21): 582.

https://doi.org/10.1182/blood.V118.21.582.582

Published: 2011

Journal Articles

High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons From the Chronic Lymphocytic Leukemia (CLL) ASCT Study by the CLL Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Liesbeth C. de Wreede, PhD, Maggie Watson, Donald Milligan, MD, MBChB, Mauricette Michallet, Peter Dreger, Prof. Dr. med., Marleen van Os, Claire E. Dearden, Catherine Cordonnier, Michel Leporrier, MD, Vladimir Koza, MD, Janis Homewood, Bernadette Corront, MD, Gabriela M. Baerlocher, MD, Wolfgang Herr, Dietger Niederwieser, MD, Laurent Sutton, Theo M. de Witte, MD, Johannes Schetelig, MD

Blood (2011) 118 (21): 1989.

https://doi.org/10.1182/blood.V118.21.1989.1989

Published: 2011

Journal Articles

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Mauricette Michallet, Peter Dreger, Laurent Sutton, Ronald Brand, Sue Richards, Marleen van Os, Mohamad Sobh, Sylvain Choquet, Bernadette Corront, Claire Dearden, Alois Gratwohl, Wolfgang Herr, Daniel Catovsky, Michael Hallek, Theo de Witte, Dietger Niederwieser, Michel Leporrier, Donald Milligan

Blood (2011) 117 (5): 1516–1521.

https://doi.org/10.1182/blood-2010-09-308775

Published: 2011

NARROW

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Symptom Burden and Health-Related Quality Of Life (HRQoL) In Patients With Myelofibrosis (MF) Treated With Fedratinib (SAR302503) In a Phase III Study (JAKARTA)

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only